Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Korro Bio (KRRO) granted nonstatutory stock options under its 2026 Inducement Plan to three newly hired employees, effective September 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Korro Bio (KRRO) granted nonstatutory stock options under its 2026 Inducement Plan to three newly hired employees, effective September 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options cover an aggregate of 5,000 shares of common stock at an exercise price of $12.93 per share, equal to the closing price on the grant date. Each option has a ten-year term and vests over four years, with 25% of the shares vesting on the first anniversary of the employee’s start date and the remaining 75% vesting in 36 equal monthly installments, subject to continued service. The grants were approved by Korro’s independent Compensation Committee as an inducement for employment.

News Explained

The grant is an option rather than a present share issuance: up to 5,000 additional common shares could be issued if the options vest and are exercised, which could dilute existing holders; the exercise price is $12.93 per share.

Market Context

5,000 shares were granted in the current inducement award; comparable Korro notices on Aug 14 and Ju...

Analysis

5,000 shares were granted in the current inducement award; comparable Korro notices on Aug 14 and Jul 10 were followed by -1.05% and -7.28% 24-hour reactions, respectively.

Key Figures

Shares granted: 5,000 shares Exercise price: $12.93 per share Option term: 10 years +3 more

Shares granted

5,000 shares

Aggregate options granted to three newly hired employees

Exercise price

$12.93 per share

Grant effective September 9, 2026

Option term

10 years

Term for each non-statutory stock option

Vesting period

Four years

Subject to continued service through applicable vesting dates

Initial vesting

25%

Vests on the first anniversary of each employee's start date

Remaining vesting

75%

Vests in 36 equal monthly installments thereafter

Historical Context

2 past events · Latest: Aug 14

2 events

1. Aug 14

   Inducement stock grant

   24h Move

   -1.1%

   One new employee received options under the 2026 Inducement Plan

2. Jul 10

   Inducement stock grants

   24h Move

   -7.3%

   Seven new employees received options under the 2026 Inducement Plan

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-statutory stock options, nasdaq listing rule 5635(c)(4), adar proteins, galnac

4 terms

non-statutory stock options financial

"grant of non-statutory stock options to three newly hired employees"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

adar proteins technical

"through ADAR proteins (Adenosine Deaminases Acting on RNA)"

Proteins in the ADAR family are enzymes that chemically edit RNA by changing specific adenosine letters into inosine, which cells read as guanosine; this editing can alter how genes are expressed without changing the underlying DNA. Investors care because ADAR activity is central to some drug and diagnostic strategies—like RNA therapeutics, biomarkers, and gene‑editing platforms—so discoveries or regulatory changes around ADARs can affect the value and risk of related biotech programs.

galnac medical

"including N-acetylgalactosamine (GalNAc) conjugated for delivery"

GalNAc is a small sugar-based molecule used as a molecular "address label" attached to certain drugs and genetic medicines so they are taken up efficiently and selectively by liver cells. For investors, GalNAc matters because it can increase a therapy’s effectiveness and safety at lower doses, improving clinical success odds, regulatory prospects, and potential commercial value—like putting the right address on a package to ensure it reaches its destination.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to three newly hired employees.

Korro granted the new employees nonstatutory stock options to purchase 5,000 shares of Korro’s common stock, in the aggregate, at an exercise price of $12.93 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, September 9, 2026. The options each have a ten-year term and vest over four years, with 25% of the shares vesting on the first anniversary of each such employee’s applicable start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of such employee’s applicable start date, subject to the employee’s continued service with Korro through each applicable vesting date.

These grants were approved by Korro’s independent Compensation Committee pursuant to Korro’s 2026 Inducement Plan and were made as an inducement material to the employee’s acceptance of employment with Korro in accordance with Nasdaq Listing Rule 5635(c)(4).

About Korro

Korro is a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of oligonucleotides that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of oligonucleotides, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro Bio Contact Information

Investor & Media Contact 
Malini Chatterjee, Ph.D
Blueprint Life Science Group
mchatterjee@bplifescience.com or ir@korrobio.com
917.330.4269